Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of 2-dose and 3-dose V160 CMV vaccine regimens in healthy CMV-seronegative women
2017-004233-86Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2018
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of V160 in cytomegalovirus disease (CMV) (3 arms), sponsored by Merck & Co. Primary endpoint: Efficacy: number of participants with CMV infection in the V160 3-dose regimen and placebo arms. Started Apr 2018; status: completed.
02
Drugs
V160
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2017-004233-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004233-86.